The Competition Appeal Tribunal has dismissed pharmaceutical company Lexon’s appeal against a £1.2m fine for breaking competition law. 

Bipolar disorder drug Priadel will be made available to patients at a reasonable price for the next five years.

Essential agrees to continue to supply lithium drug in UK for at least five years.

The CMA has launched investigations into four retailers, including pharmacies, suspected of charging “excessive and unfair prices”.

A director of a pharmaceutical manufacturer has been barred from holding a directorship at any UK company after admitting to his role in two separate anticompetitive agreements.

CMA says it will defend an appeal brought by Lexon against a £1.2m fine for allegedly sharing commercially sensitive information.

Systemic change is needed to stop pharmaceutical companies paying off rivals to keep cheaper generic drugs out of the market, UEA academics have warned.

The CMA’s Covid-19 Taskforce received almost 21,000 complaints between 10 March and 19 April.

Pharmacy contractors are reporting that wholesaler prices for paracetamol have risen substantially in recent weeks.

Wholesaler Lexon (UK) has been fined although it denies any infringement.

The European Court of Justice has upheld a UK decision that GSK and other companies entered an illegal agreement.

The CMA alleges Aspen agreed to pay Amilco and Tiofarma to stay out of the UK market for Addison’s Disease medicine.

Two companies involved in an investigation into the supply of nortriptyline have confessed to illegal collusion.

A pharmaceutical company has offered to pay the NHS £8m following an investigation into suspected collusion.

AMCo, Morningside and Alliance Healthcare have been accused of illegal market sharing over nitrofurantoin.

Four pharmaceutical companies have provisionally been found to have broken competition law.

The Competition and Markets Authority has accused four pharma companies of illegal anti-competitive behaviour, said to have cost the NHS millions

The CMA has provisionally found that two companies had an illegal anti-competitive agreement on the drug